<DOC>
	<DOCNO>NCT01050998</DOCNO>
	<brief_summary>The primary objective study assess safety , tolerability efficacy multiple dos mavrilimumab ( CAM-3001 ) administer subcutaneously subject moderately active Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CAM-3001 ( Drug ) Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind , placebo-controlled , multiple ascend dose study evaluate efficacy safety multiple dos mavrilimumab ( CAM-3001 ) ( 10 milligram [ mg ] , 30 mg , 50 mg , 100 mg ) administer subcutaneously adult subject moderately active RA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 80 year ( 20 75 year Japan ) Written consent Diagnosis adult onset Rheumatoid Arthritis ( RA ) least 3 month duration define 1987 American College Rheumatology ( ACR ) classification criterion ( Arnett et al , 1988 ) Treatment methotrexate stable tolerated dos Positive anticyclic citrullinated peptide ( CCP ) immunoglobulin G antibody ( [ &gt; ] 5 international unit per milliliter [ IU/mL ] ) and/or rheumatoid factor ( RF &gt; 14 IU/mL ) screen Received equal ( &gt; = ) 5 milligram ( mg ) per week folic acid single divide dose study . A rheumatic autoimmune disease RA A history , current , inflammatory joint disease RA systemic autoimmune disorder Subjects high risk infection Subjects ( male female ) reproductive potential willing use contraception screen end date trial History methotrexate druginduced lung fibrosis pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Mavrilimumab</keyword>
	<keyword>CAM-3001</keyword>
</DOC>